Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China
· Delayed Price · Currency is CNY 94.03
-3.30 (-3.39%)
Mar 9, 2026, 3:00 PM CST
SHA:688578 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 5,172 | 3,558 | 2,018 | 790.94 | 530.08 | Upgrade
|
| Other Revenue | - | 0.04 | 0.06 | 0.06 | 0.02 | Upgrade
|
| Revenue | 5,172 | 3,558 | 2,018 | 791 | 530.09 | Upgrade
|
| Revenue Growth (YoY) | 45.36% | 76.29% | 155.14% | 49.22% | 94409.97% | Upgrade
|
| Cost of Revenue | - | 168.99 | 110.02 | 47.11 | 29.95 | Upgrade
|
| Gross Profit | 5,172 | 3,389 | 1,908 | 743.9 | 500.14 | Upgrade
|
| Selling, General & Admin | - | 1,578 | 1,052 | 524.11 | 366.44 | Upgrade
|
| Research & Development | - | 288.99 | 280.92 | 175.71 | 200.61 | Upgrade
|
| Other Operating Expenses | 2,602 | 46.81 | 26.6 | 5.11 | 2.79 | Upgrade
|
| Operating Expenses | 2,602 | 1,914 | 1,360 | 705.26 | 569.95 | Upgrade
|
| Operating Income | 2,569 | 1,475 | 548.3 | 38.64 | -69.81 | Upgrade
|
| Interest Expense | - | -0.07 | -0.16 | -0.33 | -0.61 | Upgrade
|
| Interest & Investment Income | - | 67.04 | 60.19 | 33.06 | 30.06 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.9 | 4.35 | 17.17 | -3.38 | Upgrade
|
| Other Non Operating Income (Expenses) | -38.26 | 0.17 | 0.99 | -1.06 | -0.43 | Upgrade
|
| EBT Excluding Unusual Items | 2,531 | 1,544 | 613.68 | 87.47 | -44.16 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 28.89 | 22.67 | 32.36 | 48.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.01 | -0.02 | -1.68 | -0.57 | Upgrade
|
| Other Unusual Items | - | 45.66 | 19.89 | 7.85 | 14.88 | Upgrade
|
| Pretax Income | 2,531 | 1,619 | 656.22 | 126 | 18.27 | Upgrade
|
| Income Tax Expense | 349.81 | 188.67 | 12.05 | -4.52 | - | Upgrade
|
| Net Income | 2,181 | 1,430 | 644.17 | 130.52 | 18.27 | Upgrade
|
| Net Income to Common | 2,181 | 1,430 | 644.17 | 130.52 | 18.27 | Upgrade
|
| Net Income Growth | 52.55% | 121.97% | 393.54% | 614.22% | - | Upgrade
|
| Shares Outstanding (Basic) | 450 | 450 | 450 | 450 | 457 | Upgrade
|
| Shares Outstanding (Diluted) | 450 | 450 | 450 | 450 | 457 | Upgrade
|
| Shares Change (YoY) | 0.03% | -0.18% | 0.09% | -1.49% | 23.59% | Upgrade
|
| EPS (Basic) | 4.85 | 3.18 | 1.43 | 0.29 | 0.04 | Upgrade
|
| EPS (Diluted) | 4.85 | 3.18 | 1.43 | 0.29 | 0.04 | Upgrade
|
| EPS Growth | 52.52% | 122.38% | 393.10% | 625.00% | - | Upgrade
|
| Free Cash Flow | - | 1,296 | 606.77 | -52.21 | -162.95 | Upgrade
|
| Free Cash Flow Per Share | - | 2.88 | 1.35 | -0.12 | -0.36 | Upgrade
|
| Dividend Per Share | - | 0.650 | 0.400 | - | - | Upgrade
|
| Dividend Growth | - | 62.50% | - | - | - | Upgrade
|
| Gross Margin | 100.00% | 95.25% | 94.55% | 94.05% | 94.35% | Upgrade
|
| Operating Margin | 49.68% | 41.45% | 27.17% | 4.88% | -13.17% | Upgrade
|
| Profit Margin | 42.18% | 40.19% | 31.92% | 16.50% | 3.45% | Upgrade
|
| Free Cash Flow Margin | - | 36.42% | 30.06% | -6.60% | -30.74% | Upgrade
|
| EBITDA | 2,606 | 1,511 | 585.25 | 58.8 | -56 | Upgrade
|
| EBITDA Margin | 50.38% | 42.48% | 29.00% | 7.43% | -10.56% | Upgrade
|
| D&A For EBITDA | 36.32 | 36.32 | 36.94 | 20.16 | 13.81 | Upgrade
|
| EBIT | 2,569 | 1,475 | 548.3 | 38.64 | -69.81 | Upgrade
|
| EBIT Margin | 49.68% | 41.45% | 27.17% | 4.88% | -13.17% | Upgrade
|
| Effective Tax Rate | 13.82% | 11.66% | 1.84% | - | - | Upgrade
|
| Revenue as Reported | - | 3,558 | 2,018 | 791 | 530.09 | Upgrade
|
| Advertising Expenses | - | 863.51 | 552.06 | 201.38 | 22.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.